Thryv Therapeutics to Present at UBS Global Biopharma Conference

SAN FRANCISCO, Nov. 12, 2026 /CourierPR/ -- Thryv Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for inherited channelopathies, cardiometabolic diseases, and cardiomyopathies, will participate in the UBS Global Biopharma Conference in London from November 16 to 17, 2026. The company’s CEO, Paul Truex, will present at the event.

During his presentation, Truex will provide an update on the company’s pipeline progress, including the recent $30 million Series B financing, which was led by InClin, Inc., and continues to be supported by existing investors. The financing will help Thryv Therapeutics advance its lead candidate, THRV-1268, which is currently being evaluated in two clinical trials.

THRV-1268 is a potent and highly selective inhibitor of serum glucocorticoid inducible kinase 1 (SGK1), a protein that plays a crucial role in the intersection of electrical and structural heart disease. The company’s lead candidate is being evaluated in the Wave II Phase 2/3 study for Long QT Syndrome (LQT2 and LQT3) and the ASPIRE-HF Phase 2a study for heart failure with reduced ejection fraction (HFrEF) and QTc prolongation.

The Wave II Phase 2/3 study, which is enrolling patients, is expected to provide data in early 2027. Thryv Therapeutics has also established clinical operations in Australia, preparing for the enrollment opening of the ASPIRE-HF study in early 2027.

Thryv Therapeutics’ focus on SGK1 inhibitors is based on the understanding that the protein drives the inflammation and fibrosis leading to adverse structural remodeling in the heart. By targeting SGK1, the company aims to develop precision therapies that can address a range of heart conditions, including inherited channelopathies, cardiometabolic diseases, and cardiomyopathies.

The company’s participation in the UBS Global Biopharma Conference is a significant milestone, as it provides an opportunity to engage with investors and stakeholders, share progress updates, and discuss future plans. The conference will feature a fireside chat and one-on-one investor meetings, offering Thryv Therapeutics a platform to showcase its innovative approach to treating complex heart conditions.

In summary, Thryv Therapeutics Inc. is poised to make significant strides in the development of precision therapies for inherited channelopathies, cardiometabolic diseases, and cardiomyopathies through its pipeline of potent and highly selective inhibitors of SGK1. The company’s participation in the UBS Global Biopharma Conference in London is a testament to its commitment to advancing innovative treatments for heart conditions.